Last 7 days
-3.5%
Last 30 days
-10.9%
Last 90 days
-11.8%
Trailing 12 Months
-12.8%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 404.8B | 94.9B | -5.16% | -10.64% | 22.56 | 4.26 | 1.25% | -14.07% |
LLY | 296.8B | 28.5B | -5.67% | 20.74% | 47.53 | 10.4 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.4B | 100.3B | -8.43% | -20.95% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 142.7B | 46.2B | -7.78% | -1.12% | 22.55 | 3.09 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.8B | 4.5B | -0.20% | -5.41% | -34.17 | 1.08 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.74 | 2.63 | 18.18% | -18.59% |
CGC | 991.7M | 478.9M | -11.35% | -65.42% | -0.32 | 2.07 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 768.8M | 114.5M | -15.28% | -37.42% | -4.56 | 6.72 | 27.90% | 57.40% |
ACRS | 541.5M | 29.8M | -40.95% | -47.43% | -6.23 | 18.2 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 2.1% | 3,659 | 3,584 | 3,481 | 3,300 | 3,094 |
S&GA Expenses | -1.1% | 1,417 | 1,432 | 1,437 | 1,500 | 1,452 |
EBITDA | -623.5% | -342 | -47.34 | -54.66 | -122 | - |
EBITDA Margin | -608.6% | -0.09* | -0.01* | -0.02* | -0.04* | - |
Earnings Before Taxes | -380.3% | -372 | -77.62 | -85.12 | -242 | -112 |
EBT Margin | -370.4% | -0.10* | -0.02* | -0.02* | -0.07* | - |
Interest Expenses | - | 138 | - | - | - | - |
Net Income | -1099.0% | -224 | -18.69 | -51.87 | -449 | -329 |
Net Income Margin | -1074.3% | -0.06* | -0.01* | -0.01* | -0.14* | - |
Free Cahsflow | 15.3% | 1,243 | 1,078 | 921 | 665 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 4.3% | 10,835 | 10,385 | 11,200 | 11,769 | 12,299 |
Current Assets | 1.3% | 2,606 | 2,572 | 2,591 | 2,501 | 2,611 |
Cash Equivalents | 5.0% | 881 | 839 | 711 | 491 | 591 |
Inventory | -1.9% | 714 | 728 | 862 | 985 | 1,073 |
Goodwill | 6.3% | 1,693 | 1,593 | 1,688 | 1,782 | 1,828 |
Current Liabilities | 14.8% | 933 | 813 | 705 | 737 | 809 |
Long Term Debt | -4.9% | 5,727 | 6,021 | 6,024 | 6,050 | - |
LT Debt, Current | 0% | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 |
LT Debt, Non Current | 0.0% | 5,693 | 5,696 | 5,990 | 5,993 | 6,019 |
Shareholder's Equity | 12.4% | 3,086 | 2,745 | 3,201 | 3,608 | 3,965 |
Retained Earnings | -24.7% | 734 | 974 | 994 | 959 | 830 |
Additional Paid-In Capital | 2.6% | 3,477 | 3,388 | 3,312 | 3,239 | 3,535 |
Shares Outstanding | 0.6% | 63.00 | 62.00 | 62.00 | 62.00 | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 14.8% | 1,272 | 1,108 | 964 | 702 | 779 |
Share Based Compensation | 4.0% | 222 | 214 | 210 | 205 | 189 |
Cashflow From Investing | -238.2% | -446 | -131 | -163 | -5,986 | -5,212 |
Cashflow From Financing | 33.5% | -529 | -795 | -971 | 3,681 | 3,971 |
Buy Backs | -25.0% | 0.00 | 0.00 | 0.00 | 0.00 | - |
69.6%
49.6%
0%
Y-axis is the maximum loss one would have experienced if Jazz Pharmaceuticals was unfortunately bought at previous high price.
8.6%
1.6%
-2.6%
6.6%
FIve years rolling returns for Jazz Pharmaceuticals.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -32.2 | -20,389,000 | 87,136,000 | 0.10% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 4,764 | 26,764 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 4.74 | 1,244,000 | 6,182,000 | 0.03% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | reduced | -7.69 | -88.00 | 1,912 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -25.54 | -973,130 | 7,870,870 | 0.01% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | 2,152 | 11,152 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 0.51 | 4,173,000 | 24,896,000 | 0.26% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -3.24 | 52,530 | 385,530 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 11.01 | 1,191,840 | 4,839,840 | 0.01% |
2023-02-17 | TRUIST FINANCIAL CORP | added | 6.62 | 1,244,580 | 5,776,580 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 9.61% | 6,050,625 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 10.6% | 6,652,382 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 10.6% | 6,652,382 | SC 13G | |
Jan 05, 2023 | jpmorgan chase & co | 4.6% | 2,924,604 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Jan 28, 2022 | blackrock inc. | 10.5% | 6,450,368 | SC 13G/A | |
Jan 24, 2022 | jpmorgan chase & co | 5.2% | 3,248,156 | SC 13G | |
Feb 11, 2021 | renaissance technologies llc | 5.56% | 3,099,050 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 8.76% | 4,877,893 | SC 13G/A | |
Feb 08, 2021 | fmr llc | - | 0 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 89.88 -34.50% | 110.26 -19.65% | 153.07 11.55% | 198.25 44.48% | 231.66 68.82% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 10, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-08 | Sablich Kim | sold | -421,043 | 139 | -3,013 | evp, gm of u.s., commercial ma |
2023-03-07 | O'Keefe Kenneth W | acquired | 367,920 | 81.76 | 4,500 | - |
2023-03-07 | Larkin Finbar | sold | -292,081 | 140 | -2,075 | svp, technical operations |
2023-03-07 | O'Keefe Kenneth W | sold | -372,268 | 138 | -2,690 | - |
2023-03-06 | Larkin Finbar | acquired | 100,176 | 58.72 | 1,706 | svp, technical operations |
2023-03-06 | Larkin Finbar | sold | -245,526 | 143 | -1,706 | svp, technical operations |
2023-03-05 | Patil Neena M | sold (taxes) | -274,566 | 142 | -1,923 | evp & chief legal officer |
2023-03-05 | Carr Patricia | sold | -161,594 | 140 | -1,148 | svp, chief accounting officer |
2023-03-05 | Iannone Robert | sold (taxes) | -324,682 | 142 | -2,274 | evp, global head of research a |
2023-03-05 | Swisher Daniel N JR | sold (taxes) | -774,724 | 142 | -5,426 | president and coo |
CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues: | |||
Total revenues | $ 3,659,374 | $ 3,094,238 | $ 2,363,567 |
Operating expenses: | |||
Cost of product sales (excluding amortization of acquired developed technologies) | 540,517 | 440,760 | 148,917 |
Selling, general and administrative | 1,416,967 | 1,451,683 | 854,233 |
Research and development | 590,453 | 505,748 | 335,375 |
Intangible asset amortization | 599,169 | 525,769 | 259,580 |
Impairment charge | 133,648 | 0 | 136,139 |
Acquired in-process research and development | 444,148 | 0 | 251,250 |
Total operating expenses | 3,724,902 | 2,923,960 | 1,985,494 |
Income (loss) from operations | (65,528) | 170,278 | 378,073 |
Interest expense, net | (288,242) | (278,766) | (99,707) |
Foreign exchange loss | (19,014) | (4,350) | (3,271) |
Income (loss) before income tax expense (benefit) and equity in loss of investees | (372,784) | (112,838) | 275,095 |
Income tax expense (benefit) | (158,645) | 216,116 | 33,517 |
Equity in loss of investees | 9,921 | 714 | 2,962 |
Net income (loss) | $ (224,060) | $ (329,668) | $ 238,616 |
Net income (loss) per ordinary share: | |||
Basic (in dollars per share) | $ (3.58) | $ (5.52) | $ 4.28 |
Diluted (in dollars per share) | $ (3.58) | $ (5.52) | $ 4.22 |
Weighted-average ordinary shares used in per share calculations - basic (in shares) | 62,539 | 59,694 | 55,712 |
Weighted-average ordinary shares used in per share calculations - diluted (in shares) | 62,539 | 59,694 | 56,517 |
Product sales, net | |||
Revenues: | |||
Total revenues | $ 3,641,429 | $ 3,079,001 | $ 2,346,660 |
Royalties and contract revenues | |||
Revenues: | |||
Total revenues | $ 17,945 | $ 15,237 | $ 16,907 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 881,482 | $ 591,448 |
Accounts receivable, net of allowances of $17,843 and $13,813 at December 31, 2022 and 2021, respectively | 651,493 | 563,360 |
Inventories | 714,061 | 1,072,721 |
Prepaid expenses | 91,912 | 131,413 |
Other current assets | 267,192 | 252,392 |
Total current assets | 2,606,140 | 2,611,334 |
Property, plant and equipment, net | 228,050 | 256,837 |
Operating lease assets | 73,326 | 86,586 |
Intangible assets, net | 5,794,437 | 7,152,328 |
Goodwill | 1,692,662 | 1,827,609 |
Deferred tax assets, net | 376,247 | 311,103 |
Deferred financing costs | 9,254 | 12,029 |
Other non-current assets | 55,139 | 40,813 |
Total assets | 10,835,255 | 12,298,639 |
Current liabilities: | ||
Accounts payable | 90,758 | 100,298 |
Accrued liabilities | 803,255 | 666,304 |
Current portion of long-term debt | 31,000 | 31,000 |
Income taxes payable | 7,717 | 9,608 |
Deferred revenue | 463 | 2,093 |
Total current liabilities | 933,193 | 809,303 |
Deferred revenue, non-current | 0 | 463 |
Long-term debt, less current portion | 5,693,341 | 6,018,943 |
Operating lease liabilities, less current portion | 71,838 | 87,200 |
Deferred tax liabilities, net | 944,337 | 1,300,541 |
Other non-current liabilities | 106,812 | 116,998 |
Commitments and contingencies (Note 14) | ||
Shareholders’ equity: | ||
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 63,214 and 61,633 shares issued and outstanding at December 31, 2022 and 2021, respectively | 6 | 6 |
Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2022 and 2021 | 55 | 55 |
Capital redemption reserve | 472 | 472 |
Additional paid-in capital | 3,477,124 | 3,534,792 |
Accumulated other comprehensive loss | (1,125,509) | (400,360) |
Retained earnings | 733,586 | 830,226 |
Total shareholders’ equity | 3,085,734 | 3,965,191 |
Total liabilities and shareholders’ equity | $ 10,835,255 | $ 12,298,639 |